the 1-dehydro-analogues have exhibited no such increase in electrolyte activity and the partial dissociation of this effect has made them useful therapeutically. Clinical experience with prednisone and prednisolone has demonstrated, however, that they share most of the other shortcomings of the older steroids and, according to some investigators, they have seemed to promote such complications as peptic ulcers and ecchymotic skin lesions with greater frequency (Bunim, Pechet, and Bollet, 1955; Bollet, Black, and Bunim, 1955; Boland, 1956) . Hence the quest for more suitable anti-inflammatory steroids has continued. Hogg, Lincoln, Jackson, and Schneider (1955) and Spero, Thompson, Magerlein, Hanze, Murray, Sebek, and Hogg (1956) synthesized a series of methylated corticosteroids. Biologic experiments with these compounds indicated that when a methyl radical was substituted for a hydrogen atom at the second carbon position of the steroid nucleus, the sodium-retaining and potassium-losing effects of 11-hydroxy-corticosteroids were enhanced (Spero and others, 1956; Byrnes, Barnes, Bowman, Dulin, Morley, and Stafford, 1956) . But if the methyl grouping were introduced at the 6th carbon position instead, no such increase in electrolyte activity resulted. Preliminary studies in animals with one of the methyl derivatives (6-alpha-methyl-prednisolone) suggested that this compound might have therapeutic promise. Lyster, Barnes, Lund, Meinzinger, and Byrnes (1956) and Glenn, Stafford, Lyster, and Bowman (1957) found the rat-liverglycogen depositing activity of the compound to be sixteen times that of hydrocortisone on oral administration and ten times that of hydrocortisone on subcutaneous administration; the potency ratio of 6-methyl prednisolone to prednisolone was calculated as 3: 1. The anti-inflammatory potency of 6-methyl-prednisolone, as gauged by the granulomapouch procedure of Selye, was 5 5 times that of hydrocortisone and twice that of prednisolone. Its mean biologic half-life in dogs was determined to be 1 -56 and -14 times that of hydrocortisone and prednisolone respectively. Sodium and water retention did not develop in rats at any dose level tested.
Present Investigation The data derived from studies in animals appeared sufficiently interesting to warrant evaluations of 6-alpha-methyl-prednisolone in human subjects. Observations of certain metabolic changes induced by the compound were made by one of us (G.W.L.) and clinical trials in patients with rheumatoid arthritis were conducted by the other (E.W.B.). The studies were accomplished independently and the results were then integrated for this report.
Metabolic Studies.-Detailed analyses were carried out in seven subjects (three normal men, three normal women, and one 20-year-old woman with gonadal agenesis) while they were being maintained on a constant dietary intake. Complete collections of urine over 24-hr periods were analysed for sodium and potassium (by flame photometry), for nitrogen (by semi-micro-Kjeldahl technique), for 17-hydroxycorticoids (by the method of Silber and Porter (1954) , modified by Peterson, Wyngaarden, Guerra, Brodie, and Bunim, 1955) , and for 17-ketosteroids (Zimmerman reaction, described by Callow, Callow, and Emmens, 1938 , following hydrolysis and extraction by the method of Drekter, Heisler, Scism, Stern, Pearson, and McGarack, 1952) . Determinations made during control periods and during the oral administration of 6-methyl-prednisolone and of prednisolone were compared. The steroids were administered in either three or four equally divided doses throughout the day. In various subjects the total daily dosage of each steroid ranged from 7-5 to 60 mg.
Assays of eosinopenic activity after single oral doses of 6-methyl-prednisolone and of prednisolone were accomplished in four normal adult subjects. Each subject received each steroid twice in doses of 2 5 mg. and twice in doses of 10 mg. Dosages were given at random, but an interval of at least 72 hrs was allowed between individual doses.
Decision as to the size and spacing of doses was prompted by preliminary observations which indicated that for both steroids a linear log-dose response relationship existed between dosages of 2-5 and 10 mg., and that recovery from a single dose of steroid tested occurred within 24 hrs. Circulating eosinophils were counted before and at 4 and 7 hours after each dose of steroid. The percentage decreases in eosinophils at 4 and 7 hours were calculated, and the average of the two values was considered as the numerical response.
Assays of the electrolyte-regulating activities of 6-methyl-prednisolone and of prednisolone were accomplished in adrenalectomized dogs by the method of Liddle, Cornfield, Casper, and Bartter (1955 Observations were made in ten patients who were given 6-methyl-prednisolone as their first steroid therapy. The general plan for dosage was the same as we have applied in the past with hydrocortisone, prednisone, and prednisolone. This consisted of initial suppressive doses followed by gradual reduction of dosage to maintenance levels. Because previous experience with steroid therapy had demonstrated that long-range results were best (especially in regard to the avoidance of adverse hormonal effects) when initial suppressive amounts were not too large, an attempt was made in each instance to begin treatment with dosages which did not exceed greatly the estimated ultimate maintenance dose. The size of the initial doses used was determined principally by the activity of the disease process in individual cases and ranged from 7-5 to 12-5 mg. per day. 6-methyl-prednisolone was administered by mouth, and the total daily requirement was divided into four doses ingested at mealtimes and at bedtime with milk or a small quantity of food. Adjustments in dosage were made by small increments or decrements of 1-25 or 2 5 mg. at a time. Complemental therapy, other than routine general measures (such as regulated rest and exercise, well-balance diet, etc.), was withheld during the study. All patients were ambulatory. The total treatment periods for the group ranged, at the time of analysis, from 12 to 27 weeks.
Comparisons of doses required for 6-methylprednisolone and for prednisolone to uphold approximately equivalent degrees of improvement were made in a total of teen patients. The method consisted of transferring from one I compound to another and determining the number ized dogs suggested that the electrolyte-regulating of milligrams of each substance needed to maintain effect of 6-methyl-prednisolone may have been a similar clinical response. Among the nineteen slightly less than that of prednisolone; the 6-methylpatients studied, each was subjected to at least two analogue was observed to be 0-6 times as potent as comparisons, and some to as many as four or five. prednisolone (mean estimate). However, the 95 per Transfers of medication were made back and forth cent. confidence limits for the estimate were 04 to from 6-methyl-prednisolone to prednisolone, time 1 1. Therefore the data do not exclude the posbeing allowed in each instance to stabilize dosage sibility that the two steroids may exert identical and response with the preparation tested. influences on electrolyte metabolism. A moderate increase in the excretion of potassium ACTH Suppression.-It has been assumed that was usually noted on the first day of treatment with decreases in urinary 17,21 -dihydroxy-20-ketoeither steroid. Withdrawal of either steroid was steroids (17-hydroxycorticoids) which follow the followed by diminished potassium excretion for administration of corticoids are secondary phenoone or two days. mena due to suppressed secretion of pituitary Studies of the sodium-retaining and potassium-adrenocorticotropic hormone (ACTH). When ceractivities of these two compounds in adrenalectom-tain corticoids, including 6-methyl-prednisolone (Table 1) .
Results of Investigation
Twelve patients with various undesired sideeffects resulting from long-term treatment with prednisone or prednisolone were selected and transferred to 6-methyl-prednisolone therapy. The individual reactions noted before and 8 to 20 weeks after the transfer of medication are recorded in These findings emphasize the disparity which may exist between assessments of anti-inflammatory activity in human subjects and in laboratory animals. The screening of new steroid compounds for their potential clinical value begins (and often ends) with assays of several physiological effects in laboratory animals. While these screening tests are essential, it is important to realize that with animal tests one is often not measuring precisely the same physiological effects as one wishes to produce in human patients. It is now evident, for example, that the relative effectiveness of steroid compounds in suppressing the manifestations of rheumatoid arthritis cannot be predicted reliably by the degree of inhibition of granuloma-pouch formation or by the degree of liver-glycogen deposition in rats. The present study was prompted by the observation that 6-methyl-prednisolone was twice as potent as prednisolone as an "anti-granuloma" agent in ratsyet clinically the compound appeared to have activity indistinguishable from that of prednisolone as an "antirheumatic" agent. It is apparent that the difficult task of screening the numerous synthetic analogues of hydrocortisone and cortisone, available now and in the future, would be greatly facilitated if more dependable laboratory tests for measuring anti-inflammatory potency could be devised. Summary The metabolic and antirheumatic effects of a new steroid analogue, 6-methyl-prednisolone, were studied in human subjects. Preliminary screening tests made in animals suggested that the compound might possess greater anti-inflammatory potency than prednisolone and perhaps augmented therapeutic efficacy. The results of the present study indicated, however, that the new compound differed in no essential from prednisolone itself.
Studies of certain metabolic effects of 6-methylprednisolone led to the following deductions:
(1) The sodium-retaining and potassium-losing activities of the compound may be slightly (but not conclusively) less than those of prednisolone.
(2) The compound appeared to be at least as powerful as prednisolone as a nitrogen-wasting agent.
(3) The compound produced the same degree of pituitary-adrenal functional inhibition as prednisolone when the two substances were given in equal milligram dosages.
(4) Reductions in the numbers of circulating eosinophils after the administration of equal milligram amounts of the new compound and of prednisolone did not differ significantly.
Clinical observations resulting from the administration of 6-methyl-prednisolone in 41 patients with active peripheral rheumatoid arthritis led to the following deductions:
(1) The character and degree of improvement in rheumatic manifestations resulting from the administration of 6-methyl-prednisolone in patients receiving the drug as initial therapy did not differ significantly from those which would be anticipated from prednisone or prednisolone given in similar milligram doses. (1) Le caractere et le degree de l'amelioration des manifestations rhumatismales obtenue a la suite de administration de la 6-methyl-prednisolone A titre de therapie initiale ne differait pas significativement de celle qu'on aurait obtenue avec la prednisone ou la prednisolone, si l'on avait donned ces substances en quantites de milligrammes gales.
(2) La comparaison directe des quantites de 6-methylprednisolone et de prednisolone necessaires pour maintenir le meme degree d'amelioration clinique suggere que le pouvoir antirhumatismal des deux substances au poids egal en milligrammes est presque, ou tout a fait, legal.
(3) On ne peut tirer que des conclusions tentatives en ce qui concerne les effets secondaires nuisibles du nouveau compose par rapport A la prednisone et la prednisolone. On peut dire, cependant, que la plupart des reactions defavorables de ces substances ont aussi et notees avec la 6-methyl-prednisolone. Les recherches n'ont pas e poussees assez loin pour determiner la tendance relative du nouveau compose A provoquer des complications telles que l'ulcere peptique ou l'osteoporose.
Accion metab6lica y antirreumatica de la 6-metil-prednisolona (Medrol) SUMARIO Los efectos metab6licos y antirreumaticos de un nuevo analogo esteroide, la 6-metil-prednisolona, fueron estudiados en sujetos humanos. Investigaciones preliminares sobre animales habian sugerido que este compuesto pudiera tener un poder anti-inflamatorio superior al de la prednisolona y que su eficacidad terapeutica fuera tambien mayor. Los resultados de los estudios presentes indican, sin embargo, que el producto nuevo no se distingue esencialmente de la prednisolona original.
Las investigaciones de ciertos efectos metab6licos de la 6-metil-prednisolona nos llevan a las conclusiones siguientes:
(1) La acci6n sobre los iones metAlicos-retenci6n de sodio y perdida de potasio-de este compuesto es, quizAs (pero no conclusivamente), algo mis debil que la de la prednisolona.
(2) El desgaste de nitr6geno con este compuesto parece ser al menos tan pronunciado como 6l con la prednisolona.
(3) En dosis iguales de miligramos, el grado de inhibici6n de la funci6n hipofiso-suprarrenal es igual para ambos compuestos. 
